Laura Brege - Jan 12, 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Jan 12, 2023
Transactions value $
-$15,500
Form type
4
Date filed
1/17/2023, 04:17 PM
Previous filing
Jun 28, 2022
Next filing
Apr 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise $213K +12.5K $17.01 12.5K Jan 12, 2023 Direct
transaction ACAD Common Stock Sale -$228K -12.5K -100% $18.25 0 Jan 12, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Options Exercise $0 -12.5K -100% $0.00* 0 Jan 12, 2023 Common Stock 12.5K $17.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2022.
F2 The option is fully vested and exercisable.